Results for 'CVD'
Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials
cancer, cardiovascular disease, clinical trials, underrepresentation, United States Food and Drug Administration, FDA, CVD
Heart failure (28%) was the most common exclusion criterion in clinical trials for FDA-approved anticancer therapies, followed by prior coronary disease and arrhythmias (27% and 23%, respectively). Over one-third of trials excluded patients with underlying cardiovascular disease (CVD), including mor…
Mar 18th • 3 mins read